Document
IPR2020-01252, No. 1009-9 Exhibit - Ex 1009 E Epperson, Mannitol Crystallization in Plastic Containers (P.T.A.B. Jul. 22, 2020)
Cite Document
IPR2020-01252, No. 1009-9 Exhibit - Ex 1009 E Epperson, Mannitol Crystallization in Plastic Containers (P.T.A.B. Jul. 22, 2020)
+ More Snippets
Document
IPR2020-01252, No. 1054-63 Exhibit - Ex 1054 Napaporn et al, Assessment of the Myotoxicity of Pharmaceutical Buffers Using an In vitro Muscle Model (P.T.A.B. Jul. 22, 2020)
Cite Document
IPR2020-01252, No. 1054-63 Exhibit - Ex 1054 Napaporn et al, Assessment of the Myotoxicity of Pharmaceutical Buffers Using an In vitro Muscle Model (P.T.A.B. Jul. 22, 2020)
+ More Snippets
Document
IPR2020-01252, No. 1058-67 Exhibit - Ex 1058 S Borchert et al, Particulate Matter in Parenteral Products (P.T.A.B. Jul. 22, 2020)
Cite Document
IPR2020-01252, No. 1058-67 Exhibit - Ex 1058 S Borchert et al, Particulate Matter in Parenteral Products (P.T.A.B. Jul. 22, 2020)
+ More Snippets
Document
IPR2020-01252, No. 1076-85 Exhibit - Ex 1076 WIPO Patentscope PCT Bibliography Data for PCTDK2004000792 (P.T.A.B. Jul. 22, 2020)
Cite Document
IPR2020-01252, No. 1076-85 Exhibit - Ex 1076 WIPO Patentscope PCT Bibliography Data for PCTDK2004000792 (P.T.A.B. Jul. 22, 2020)
+ More Snippets
Document
IPR2020-01252, No. 1050-59 Exhibit - Ex 1050 C Fox et al, Ability to Handle, and Patient Preference for, Insulin Delivery Devices in Visually Impaired Patients with Type 2 Diabetes (P.T.A.B. Jul...
Cite Document
IPR2020-01252, No. 1050-59 Exhibit - Ex 1050 C Fox et al, Ability to Handle, and Patient Preference for, Insulin Delivery Devices in Visually Impaired Patients with Type 2 Diabetes (P.T.A.B. Jul. 22
+ More Snippets
Document
IPR2020-01252, No. 1044 Exhibit - Ex 1044 International Publication No EP 0 699 686 (P.T.A.B. Jul. 22, 2020)
Cite Document
IPR2020-01252, No. 1044 Exhibit - Ex 1044 International Publication No EP 0 699 686 (P.T.A.B. Jul. 22, 2020)
+ More Snippets
Document
Novo Nordisk Inc. et al v. Teva Pharmaceuticals USA, Inc., 1:17-cv-00227, No. 39-1 (D.Del. Jan. 29, 2018)
Cite Document
Novo Nordisk Inc. et al v. Teva Pharmaceuticals USA, Inc., 1:17-cv-00227, No. 39-1 (D.Del. Jan. 29, 2018)
+ More Snippets
Document
SAXENDA, 206321, Letter (Orange Book Jun. 15, 2022)
Cite Document
SAXENDA, 206321, Letter (Orange Book Jun. 15, 2022)
+ More Snippets
Document
SAXENDA, 206321, Label (Orange Book Jun. 15, 2022)
Cite Document
SAXENDA, 206321, Label (Orange Book Jun. 15, 2022)
+ More Snippets
Document
OZEMPIC, 209637, Letter (Orange Book Mar. 28, 2022)
Cite Document
OZEMPIC, 209637, Letter (Orange Book Mar. 28, 2022)
+ More Snippets
Document
OZEMPIC, 209637, Label (Orange Book Mar. 28, 2022)
Cite Document
OZEMPIC, 209637, Label (Orange Book Mar. 28, 2022)
+ More Snippets
Document
VICTOZA, 022341, Letter (Orange Book Jun. 10, 2022)
Cite Document
VICTOZA, 022341, Letter (Orange Book Jun. 10, 2022)
+ More Snippets
Document
VICTOZA, 022341, Letter (Orange Book Jun. 10, 2022)
Cite Document
VICTOZA, 022341, Letter (Orange Book Jun. 10, 2022)
+ More Snippets
Document
VICTOZA, 022341, Label (Orange Book Jun. 10, 2022)
Cite Document
VICTOZA, 022341, Label (Orange Book Jun. 10, 2022)
+ More Snippets
Document
VICTOZA, 022341, Letter (Orange Book Jun. 10, 2022)
Cite Document
VICTOZA, 022341, Letter (Orange Book Jun. 10, 2022)
+ More Snippets